Dianthus Therapeutics vs Oramed Pharmaceuticals
Dianthus Therapeutics reported revenue of $2 million in fiscal 2025, about the same as Oramed Pharmaceuticals' $2 million in fiscal 2025. Dianthus Therapeutics had an operating margin of -8739.3%, against -754.4% at Oramed Pharmaceuticals. Free cash flow was −$129 million at Dianthus Therapeutics and −$9 million at Oramed Pharmaceuticals.
Side by side
| Dianthus Therapeutics | Oramed Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $2M |
| Revenue growth | −67.3% | — |
| Revenue growth a year, last 5 years | — | −5.8% |
| Gross margin | — | 0.7% |
| Operating margin | −8,739.3% | −754.4% |
| Net margin | −7,973.3% | 3,202.5% |
| Free cash flow | −$129M | −$9M |
| Free cash flow margin | −6,349.4% | −457.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $5M |
| Change in diluted share count | 15.9% | 3.8% |
| Last close | $84.83 | $3.69 |
| P/E at the last close | — | 1.1× |
| Insider trades, last 12 months | sold $75.1 million | sold $941,874 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Dianthus TherapeuticsOramed Pharmaceuticals
Operating margin
Percent of revenue
Dianthus TherapeuticsOramed Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dianthus TherapeuticsOramed Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dianthus Therapeutics and Oramed Pharmaceuticals pages.